Governor vessel moxibustion combined with western medication for mild to moderate depression with kidney-yang deficiency: a randomized controlled trial / 中国针灸

OBJECTIVE@#To compare the therapeutic efficacy of governor vessel moxibustion combined with fluoxetine hydrochloride capsule, simple fluoxetine hydrochloride capsule and placebo moxibustion combined with fluoxetine hydrochloride capsule for mild to moderate depression with kidney-yang deficiency.@*METHODS@#A total of 126 patients with mild to moderate depression with kidney-yang deficiency were randomized into a governor vessel moxibustion group (42 cases, 2 cases dropped off), a western medication group (42 cases, 1 case dropped off) and a placebo moxibustion group (42 cases, 1 case dropped off). The western medication group was given fluoxetine hydrochloride capsule orally, 20 mg a time, once a day. On the basis of the treatment in the western medication group, governor vessel moxibustion was applied from Dazhui (GV 14) to Yaoshu (GV 2) in the governor vessel moxibustion group, once a week; placebo moxibustion was applied in the placebo moxibustion group, once a week. Treatment of 8 weeks was required in the 3 groups. Before and after treatment, the scores of Hamilton depression scale-17 (HAMD-17), Asberg's rating scale for side effects (SERS) and TCM clinical symptom were compared, and the clinical efficacy was evaluated.@*RESULTS@#After treatment, the scores of HAMD-17, SERS and TCM clinical symptom were decreased compared before treatment in the 3 groups (P<0.05), the decrease ranges of above scores in the governor vessel moxibustion group were larger than those in the western medication group and the placebo moxibustion group (P<0.05). The total effective rate was 92.5% (37/40) in the governor vessel moxibustion group, which was higher than 75.6% (31/41) in the western medication group and 80.5% (33/41) in the placebo moxibustion group (P<0.05).@*CONCLUSION@#Governor vessel moxibustion combined with fluoxetine hydrochloride capsule can improve the degree of depression and relieve the clinical symptoms in mild to moderate depression patients with kidney-yang deficiency, the efficacy is superior to simple fluoxetine hydrochloride capsule, and can reduce the fluoxetine hydrochloride capsule-induced adverse effect to a certain extent.

Analysis on sleep quality and characteristics of depression patients with different degrees of anxiety / 上海交通大学学报（医学版）

Objective: To compare the sleep quality of depressive patients with and without anxiety symptoms. Methods: Hamilton Depression Scale-17 (HAMD-17), Hamilton Anxiety Scale (HAMA) and Pittsburgh Sleep Quality Index Scale (PSQI) were used to assess the level of patients' depression, anxiety and sleep quality. The HAMA scores of patients ranged from 0 to 6 were in the anxiety-free group, 7 to 13 in the anxiety-prone group, and 14 or more in the anxiety group. Results: The PSQI scores of the group with anxiety were higher than those of anxiety-prone group and anxiety-free group (both P=0.000). Partial correlation analysis showed that, after controlling HAMD-17 scores, the correlation between HAMA scores and PSQI scores reduced gradually with the increase of anxiety level. The multiple linear regression analysis showed that sleep disorder was still an independent risk factor for depression after controlling HAMA score. Sleep latency, sleep time, hypnotics and daytime dysfunction were independent predictive factors of HAMD-17 score (all P<0.05). Conclusion: In patients with depressive disorder, the severity of sleep disorder increases with the increase of anxiety level. In the case of comorbidity anxiety, sleep disorder is still an independent risk factor for depressive disorder, and the relationship between depressive symptoms and sleep disorder indicators of different dimensions suggests that sleep disorder plays a comprehensive role in the pathogenesis of depressive disorder.